Aligos Therapeutics, Inc.

NASDAQ:ALGS

39.34 (USD) • At close December 24, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

202320222021202020192018
Revenue 15.52913.9074.359000
Cost of Revenue 3.0693.675104.1533.3252.2991.291
Gross Profit 12.4610.232-99.794-3.325-2.299-1.291
Gross Profit Ratio 0.8020.736-22.894000
Reseach & Development Expenses 73.0485.077104.15379.8944.03810.456
General & Administrative Expenses 30.61626.4128.52717.94410.0053.205
Selling & Marketing Expenses 000000
SG&A 30.61626.4128.52717.94410.0053.205
Other Expenses 000-10.5480.302-0.435
Operating Expenses 103.656111.487132.6897.83454.04313.661
Operating Income -88.127-97.58-128.321-97.834-54.043-13.661
Operating Income Ratio -5.675-7.017-29.438000
Total Other Income Expenses Net 1.2431.640.132-10.5481.864-0.272
Income Before Tax -86.884-95.94-128.189-108.382-52.179-13.933
Income Before Tax Ratio -5.595-6.899-29.408000
Income Tax Expense 0.7950.1060.1430.1610.085-0.272
Net Income -87.679-96.046-128.332-108.543-52.264-13.933
Net Income Ratio -5.646-6.906-29.441000
EPS -3.52-2.25-3.22-3.18-2.38-0.66
EPS Diluted -3.52-2.25-3.22-3.18-2.38-0.66
EBITDA -85.058-93.905-124.543-105.057-49.88-12.37
EBITDA Ratio -5.477-7.017-29.438000